NCT05959304View on ClinicalTrials.gov

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

Not yet recruitingOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

October 4, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Diabetic Macular Edema
Interventions
OTHER

brolucizumab

There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY